The objective of this article is to evaluate the impact of pregnancy in women with prolactinoma, the possible consequences of therapy maintenance/discontinuation during pregnancy and to assess the type of delivery and maternal-foetal obstetrical outcome. A retrospective study of all pregnant women with prolactinoma in our Centre between 2006 and 2014 was made. We had 35 cases of pregnant women with prolactinoma, two of which had an episode of pituitary apoplexy during the second trimester. At the time of conception, most women were being treated with 5 mg bromocriptine. The majority of women had suspended medication in the 8th week of gestation. Caesarean rate was 48.6%. The maternal foetal outcome was favourable in all cases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01443615.2016.1233946 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microprolactinoma Growth During Pregnancy With Pituitary Tumor Apoplexy: Case Report and Review of the Literature.
Case Rep Endocrinol
January 2025
Unidad Académica de Endocrinología y Metabolismo, Hospital de Clínicas "Dr. Manuel Quíntela", Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Prolactinomas are the most prevalent subtype of pituitary adenomas and represent one of the leading etiological factors responsible for amenorrhea and infertility in women. The primary therapeutic approach entails the use of dopamine agonists, which effectively restore fertility. In cases of microprolactinomas, the likelihood of experiencing a symptomatic enlargement of the tumor during pregnancy is exceptionally low, estimated at a mere 2.
View Article and Find Full Text PDFDisease activity and maternal-fetal outcomes in pregnant women with prolactinoma: A systematic review and meta-analysis.
J Clin Endocrinol Metab
November 2024
Department of Internal Medicine, São Paulo State University (UNESP), Medical School, Botucatu, São Paulo, Brazil.
Context: Women with prolactinoma are usually infertile, but can conceive after surgery or treatment with dopamine agonists (DA).
Objective: To evaluate the impact of pregnancy in prolactinoma's natural course and in maternal-fetal outcomes.
Data Sources: MEDLINE, EMBASE, LILACS, and CENTRAL.
Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications.
Arch Med Res
December 2024
Unidad de Investigación Médica en Enfermedades Endocrinas, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico. Electronic address:
Article Synopsis
- Prolactin (PRL) is a hormone from the anterior pituitary that primarily regulates breast development and milk production.
- Hyperprolactinemia, or elevated PRL levels, is a common issue in medical settings, often caused by medications like antipsychotics, though it can also stem from tumors or other health conditions.
- This condition is significant for reproductive health, contributing to infertility in about 15-20% of women and causing issues like secondary amenorrhea, while also leading to hypogonadism in men.
Elucidating Clinical Queries for Tailored Therapy in Patients with Prolactinoma.
Endocrinol Metab (Seoul)
December 2024
Division of Endocrinology, Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
Article Synopsis
- * While medication effectively reduces tumor size and hormone levels, issues such as treatment duration and side effects can impact patient adherence.
- * Recent advancements in surgical techniques and precision medicine offer opportunities for personalized treatment plans, focusing on factors like DA sensitivity, surgical suitability, and patient safety, especially during pregnancy and breastfeeding.
A multicenter study of clinical outcomes and volumetric trends in suspected microprolactinomas.
Neurosurg Rev
September 2024
Department of Neurosurgery, Computational Neurosciences Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Street, BTM 4, Boston, MA, 02115, USA.
The diagnosis of pituitary microprolactinomas is often obscured by relatively low levels of elevated prolactin compared to macroprolactinomas. This may lead to varying patterns of medical therapy versus observation. We sought to correlate prolactin levels in suspected microprolactinomas with tumor volumes and clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!